Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Caesars Entertainment Corp. (NASDAQ: CZR) shares spiked 12.81 percent to close at $15.94 a share Wednesday. The stock traded between $14.23 and $16.36 on volume of 2.01 million shares traded. The company has filed a statement with the SEC to distribute subscription rights for 125.4 million of Caesars Acquisition Co. at $9.43 each. Shares of the Caesars Entertainment have gained approximately 130.0 percent year-to-date.
Get more information on Caesars Entertainment and free access to the in-depth equity report at:
NII Holdings Inc. (NASDAQ: NIHD) shares jumped 14.33 percent to close at $7.10 a share Wednesday. The stock traded between $6.19 and $7.14 on volume of 1.98 million shares traded. On Wednesday, the company and Motorola Mobility announced the launch of PRIP push-to-talk service in the U.S.
Get more information on NII Holdings and free access to the in-depth equity report at:
Pharmacyclics, Inc. (NASDAQ: PCYC) shares surged 11.99 percent to close at $100.26 a share Wednesday. The stock traded between $93.00 and $102.05 on volume of 2.44 million shares traded. The company announced it has submitted a New Drug Application to the FDA for ibrutinib for two relapsed/refractory B-cell malignancy indications. Shares of Pharmacyclics have gained approximately 73.5 percent year-to-date.
Get more information on Pharmacyclics and free access to the in-depth equity report at:
Stemline Therapeutics Inc. (NASDAQ: STML) shares gained 12.39 percent to close at $28.22 a share Wednesday. The stock traded between $25.25 and $28.89 on volume of 483,120 shares traded. On Wednesday, Ivan Bergstein, M.D., Chief Executive Officer, presented at the 8th Annual JMP Securities Healthcare Conference. Shares of Stemline Therapeutics have gained approximately 130.0 percent year-to-date.
Get more information on Stemline Therapeutics and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities